Opus Genetics, Inc. (NASDAQ:IRD) — Market Cap & Net Worth
Market Cap & Net Worth: Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (NASDAQ:IRD) has a market capitalization of $382.72 Million ($382.72 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13714 globally and #3299 in its home market, demonstrating a 24.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Opus Genetics, Inc.'s stock price $5.41 by its total outstanding shares 71402472 (71.40 Million). Also see Opus Genetics, Inc. assets under control for a full breakdown of the balance sheet.
Opus Genetics, Inc. Market Cap History: 2015 to 2026
Opus Genetics, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $12.34 Billion to $386.29 Million (-28.94% CAGR). Also see cash efficiency ratio of Opus Genetics, Inc. for how efficiently the company converts equity into cash flow.
Index Memberships
Opus Genetics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #372 of 976 |
Weight: Opus Genetics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Opus Genetics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Opus Genetics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Opus Genetics, Inc. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
10.11x
Opus Genetics, Inc.'s market cap is 10.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $266.33 Million | $589.00K | -$56.69 Million | 452.18x | N/A |
| 2022 | $252.05 Million | $39.85 Million | $17.89 Million | 6.32x | 14.09x |
| 2023 | $214.92 Million | $19.05 Million | -$9.99 Million | 11.28x | N/A |
| 2024 | $84.97 Million | $10.99 Million | -$57.53 Million | 7.73x | N/A |
| 2025 | $143.52 Million | $14.20 Million | -$49.59 Million | 10.11x | N/A |
Competitor Companies of IRD by Market Capitalization
Companies near Opus Genetics, Inc. in the global market cap rankings as of September 17, 2026. Review Opus Genetics, Inc. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Opus Genetics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Opus Genetics, Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Opus Genetics, Inc.'s market cap moved from $12.34 Billion to $ 386.29 Million, with a yearly change of -28.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $386.29 Million | +169.15% |
| 2025 | $143.52 Million | +68.91% |
| 2024 | $84.97 Million | -60.47% |
| 2023 | $214.92 Million | -14.73% |
| 2022 | $252.05 Million | -5.36% |
| 2021 | $266.33 Million | -42.53% |
| 2020 | $463.40 Million | -15.05% |
| 2019 | $545.51 Million | -82.89% |
| 2018 | $3.19 Billion | -53.96% |
| 2017 | $6.92 Billion | +44.29% |
| 2016 | $4.80 Billion | -61.11% |
| 2015 | $12.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Opus Genetics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $382.72 Million USD |
| MoneyControl | $382.72 Million USD |
| MarketWatch | $382.72 Million USD |
| marketcap.company | $382.72 Million USD |
| Reuters | $382.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more